|
|
Corporate
-
Announcements
Ranbaxy gets nod for Biaxin generic
Our Bureau
New Delhi, Oct. 4
Ranbaxy Laboratories has received final approval
from the US Food and Drug Administration to make
and sell generic version of Abbott's anti-infective Biaxin.
The approval is for two strengths of Clarithromycin for
Oral Suspension, USP. The company said in a statement
that it was the first to
have been granted a
generic approval for
the Oral Suspension
form along with
Clarithromycin tablets.
The total annual sales
for the drug were $99.7
million with
suspension sales
totalling $25.3 million.
"We are pleased to receive this FDA approval for Clarithromycin for Oral
Suspension, an anti-infective agent that will add depth
and breadth to our product line of anti-infectives that also
includes Clarithromycin tablets. Ranbaxy
Pharmaceuticals Inc will be in a position to offer both
dosage forms for this molecule that will distinguish
Ranbaxy in the market place," said Mr Jim Meehan,
Vice-President, Sales and Distribution for the company's
Florida based subsidiary. The drug is used in the
treatment of Pharyngitis or Tonsillitis, communityacquired
pneumonia, uncomplicated skin infections and
disseminated mycobacterial infections.
More Stories on :
Announcements |
Pharmaceuticals |
Ranbaxy Laboratories Ltd
Article
E-Mail
::
Comment
::
Syndication
::
Printer Friendly Page
|
Stories in this Section
‘Launching new vehicles, the only way to grow’
Tata Steel, Corus begin joint sourcing
Gulf co buying Rane Madras’ surplus land
Ranbaxy gets nod for Biaxin generic
Impairment drill that churns oil and gas accountants
i-flex board okays additional investments
‘DLF in talks to raise Rs 2,000 cr thru pvt equity’
More private sector cos enter top advance tax payers list
McLeod Russel announces higher bonus
Exide plans 7.5% hike in prices by mid-October
Caparo plans luxury bus facility near Chennai
Multivista sets up printing unit near Chennai
Reliance Power mandates banks, FIs to raise $6 b
Bengal signs pact with Videocon, Jai Balaji
Modi lays foundation stone for gas-based plant near Hazira
Finnish co Perlos opens plant near Chennai
Osram investing Rs 100 cr in Haryana plant
Maruti’s venture with Futaba among 13 FDI plans cleared
Direct tax collections up 40.2% in April-Sept
Dabur entering malted food drinks segment
Essar Oil plans test well drilling at Ranigunj block
IHI will begin Petronet’s terminal construction in Feb
Marginal fields: ONGC told to review package
HM investing Rs 295 cr for Uttarapara unit upgrade
Addl charge for NMDC director
Padiyar takes charge at KIOCL
|
|
